SCHEMBL22423979

SCHEMBL22423979

CNC(=O)c1cc(Cl)c(N)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.54
▸ HPGD P15428 2/20 0.54
▸ HSD11B1 P28845 7/20 0.50
▸ KDM4E B2RXH2 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ SCN10A Q9Y5Y9 2/20 0.44
▸ SCN9A Q15858 1/20 0.44
▸ SCN2A Q99250 1/20 0.44
▸ SCN3A Q9NY46 1/20 0.44
▸ HDAC8 Q9BY41 2/20 0.42
▸ HDAC6 Q9UBN7 2/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ CYP3A4 P08684 1/20 0.41
▸ PLAU P00749 1/20 0.41
▸ CA2 P00918 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ PLK1 P53350 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23973915 0.89 ALDH1A1 (0.49) ALDH1A1HPGDHSD11B1KDM4EGAA
SCHEMBL11332390 0.81 KDM4E (0.61) ALDH1A1HSD11B1KDM4EGAAHDAC6
SCHEMBL879253 0.79 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EHDAC8HDAC6
SCHEMBL30071572 0.79 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EHDAC8HDAC6
SCHEMBL14060151 0.78 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EGAASCN10A
SCHEMBL14059763 0.78 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EGAASCN10A
Hydrochloric Acid SCHEMBL8742112 0.77 HSD11B1 (0.45) ALDH1A1HPGDHSD11B1KDM4EGAA
SCHEMBL1005961 0.77 HDAC6 (0.43) ALDH1A1HPGDKDM4EHDAC8HDAC6
SCHEMBL4478521 0.77 HDAC8 (0.60) ALDH1A1HPGDHDAC8HDAC6HDAC2
SCHEMBL15495178 0.76 ALDH1A1 (0.51) ALDH1A1HPGDKDM4EGAAHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020182990-A1 FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2020-09-17 — — WO disclosed
Send feedback